Latanoprost ophthalmic solution
Sponsors
Alcon Research, Aerie Pharmaceuticals, Santen Inc., Otsuka Pharmaceutical Co., Ltd., Peregrine Ophthalmic
Conditions
GlaucomaOcular HypertensionOpen Angle Glaucoma or Ocular HypertensionOpen-Angle GlaucomaOpen-angle GlaucomaOpen-angle Glaucoma or Ocular HypertensionPrimary Open Angle Glaucoma
Phase 1
Phase 2
Adjunctive Study of AL-37807 Ophthalmic Suspension
CompletedNCT00620256
Start: 2007-11-30End: 2008-07-31Updated: 2012-12-05
Study of AR-12286 Versus Latanoprost in Patients With Elevated Intraocular Pressure
CompletedNCT01060579
Start: 2010-02-28End: 2010-08-31Updated: 2014-05-08
Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
CompletedNCT01868126
Start: 2013-05-31End: 2013-09-30Updated: 2018-04-18
POLAT-001 Compared to Latanoprost Ophthalmic Solution in Patients With Ocular Hypertension and Open-angle Glaucoma
CompletedNCT02466399
Start: 2015-07-31End: 2016-04-30Updated: 2020-11-16
Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma
CompletedNCT04405245
Start: 2020-06-06End: 2020-11-05Updated: 2023-05-25
Phase 3
Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension
CompletedNCT02105272
Start: 2014-04-30End: 2015-03-31Updated: 2015-12-21
A Phase III Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost Ophthalmic Solution in Subjects With OAG or OHT
CompletedNCT02981446
Start: 2017-01-31End: 2019-01-31Updated: 2024-03-15